Fluoroquinolones as chemotherapeutics against mycobacterial infections

Current Pharmaceutical Design

Volumn 10, Issue 26, 2004, Pages 3213-3220

  Jacobs, Michael R ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluoroquinolones; Mycobacteria; Mycobacterium avium complex; Quinolones; Topoisomerase

Indexed keywords

AMIKACIN; ANTIMYCOBACTERIAL AGENT; AZITHROMYCIN; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; CLOFAZIMINE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE IV; ETHAMBUTOL; FLUMEQUINE; GATIFLOXACIN; GEMIFLOXACIN; GREPAFLOXACIN; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; NALIDIXIC ACID; OFLOXACIN; PD 161315; PEFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFABUTIN; RIFAMYCIN; SITAFLOXACIN; SPARFLOXACIN; STREPTOMYCIN; TROVAFLOXACIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ATYPICAL MYCOBACTERIOSIS; DRUG ACTIVITY; DRUG HALF LIFE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DRUG USE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INDIVIDUALIZATION; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; STRAIN DIFFERENCE; STRUCTURE ACTIVITY RELATION; TUBERCULOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MYCOBACTERIUM INFECTIONS; RETROSPECTIVE STUDIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4644269691     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043383296     Document Type: Review

References (69)

1. WHO. WHO Tuberculosis Programme: framework for effective tuberculosis control. WHO/TB 1994; 94: 179.
2. O'Brien RJ, Vernon AA. New tuberculosis drug development. How can we do better? Am J Respir Crit Care Med 1998; 157: 1705-7.
3. Iseman MD. A Clinician's Guide to Tuberculosis. First ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.
4. ATS: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. This official statement of the American Thoracic Society was approved by the Board of Directors, March 1997. Medical Section of the American Lung Association. Am J Respir Crit Care Med 1997; 156(2 Pt 2): S1-25.
5. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992; 165: 1082-5.
6. Berning SE. The role of fluoroquinolones in tuberculosis today. Drugs 2001; 61: 9-18.
7. Saito H, Tomioka H, Sato K, Dekio S. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a. Antimicrob Agents Chemother 1994; 38: 2877-82.
8. Sato K, Tomioka H, Sano C, Shimizu T, Sano K, Ogasawara K, et al. Comparative antimicrobial activities of gatifloxacin, sitafloxacin and levofloxacin against Mycobacterium tuberculosis replicating within Mono Mac 6 human macrophage and A-549 type II alveolar cell lines. J Antimicrob Chemother 2003; 52: 199-203.
9. Gillespie SH, Morrissey I, Everett D. A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 2001; 50: 565-70.
10. Jacobs MR. Activity of quinolones against mycobacteria. Drugs 1999; 58: 19-22.
11. Renau TE, Gage JW, Dever JA, Roland GE, Joannides ET, Shapiro MA, et al. Structure-activity relationships of quinolone agents against mycobacteria: effect of structural modifications at the 8 position. Antimicrob Agents Chemother 1996; 40: 2363-8.
12. Gonzalez I, Georgiou M, Alcaide F, Balas D, Linares J, de la Campa AG. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci. Antimicrob Agents Chemother 1998; 42: 2792-8.
13. Guillemin I, Jarlier V, Cambau E. Correlation between quinolone susceptibility patterns and sequences in the A and B subunits of DNA gyrase in mycobacteria. Antimicrob Agents Chemother 1998: 42: 2084-8.
14. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA. Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995; 39: 1700-3.
15. Kocagoz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF. Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996; 40: 1768-74.
16. Liu J, Takiff HE, Nikaido H. Active efflux of fluoroquinolones in Mycobacterium smegmatis mediated by LfrA, a multidrug efflux pump. J Bacteriol 1996; 178: 3791-5.
17. Yajko DM, Sanders CA, Madej JJ, Cawthon VL, Hadley WK. In vitro activities of rifabutin, azithromycin, ciprofloxacin, clarithromycin, clofazimine, ethambutol, and amikacin in combinations of two, three, and four drugs against Mycobacterium avium. Antimicrob Agents Chemother 1996: 40: 743-9.
18. Rastogi N, Goh KS, Bryskier A, Devallois A. Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine. Antimicrob Agents Chemother 1996; 40: 2483-7.
19. Rastogi N, Labrousse V, Goh KS. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages. Curr Microbiol 1996; 33: 167-75.
20. Perronne C, Gikas A, Truffot-Pernot C, Grosset J, Vilde JL, Pocidalo JJ. Activities of sparfloxacin, azithromycin, temafloxacin, and rifapentine compared with that of clarithromycin against multiplication of Mycobacterium avium complex within human macrophages. Antimicrob Agents Chemother 1991; 35: 1356-9.
21. Rastogi N, Labrousse V, Goh KS, De Sousa JP. Antimycobacterial spectrum of sparfloxacin and its activities alone and in association with other drugs against Mycobacterium avium complex growing extracellularly and intracellularly in murine and human macrophages. Antimicrob Agents Chemother 1991; 35: 2473-80.
22. Duzgunes N, Flasher D, Reddy MV, Luna-Herrera J, Gangadharam PR. Treatment of intracellular Mycobacterium avium complex infection by free and liposome-encapsulated sparfloxacin. Antimicrob Agents Chemother 1996; 40: 2618-21.
23. Klopman G, Fercu D, Renau TE, Jacobs MR. N-1-tert-butyl-substituted quinolones: in vitro anti-Mycobacterium avium activities and structure-activity relationship studies. Antimicrob Agents Chemother 1996; 40: 2637-43.
24. Ji B, Lounis N, Truffot-Pernot C, Grosset J. In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1995; 39: 1341-4.
25. Lounis N, Ji B, Truffot-Pernot C, Grosset J. Which aminoglycoside or fluoroquinolone is more active against Mycobacterium tuberculosis in mice? Antimicrob Agents Chemother 1997; 41: 607-10.
26. Lalande V, Truffot-Pernot C, Paccaly-Moulin A, Grosset J, Ji B. Powerful bactericidal activity of sparfloxacin (AT-4140) against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 1993; 37: 407-13.
27. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998; 42: 2066-9.
28. Miyazaki E, Miyazaki M, Chen JM, Chaisson RE, Bishai WR. Moxifloxacin (BAY 12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. Antimicrob Agents Chemother 1999; 43: 85-9.
29. Alvirez-Freites EJ, Carter JL, Cynamon MH. In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2002; 46: 1022-5.
30. Woodcock JM, Andrews JM, Boswell FJ, Brenwald NP, Wise R. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997; 41: 101-6.
31. Lounis N, Bentoucha A, Truffot-Pernot C, Ji B, O'Brien RJ, Vernon A, et al. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice. Antimicrob Agents Chemother 2001; 45: 3482-6.
32. Yoshimatsu T, Nuermberger E, Tyagi S, Chaisson R, Bishai W, Grosset J. Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis. Antimicrob Agents Chemother 2002; 46: 1875-9.
33. Bermudez LE, Inderlied CB, Kolonoski P, Petrofsky M, Aralar P, Wu M, et al. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium. Antimicrob Agents Chemother 2001; 45: 217-22.
34. Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Young LS. SRI-286 (a thiosemicarbide) in combination with mefloquine (MFQ) and moxifloxacin (MXF) for treatment of murine M. avium complex disease (MAC). In: Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, 2003.
35. Bermudez LE, Kolonoski P, Petrofsky M, Wu M, Inderlied CB, Young LS. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease. J Infect Dis 2003; 187: 1977-80.
36. Tomioka H, Sato K, Akaki T, Kajitani H, Kawahara S, Sakatani M. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 1999; 43: 3001-4.
37. Tomioka H, Saito H, Sato K. Comparative antimycobacterial activities of the newly synthesized quinolone AM-1155, sparfloxacin, and ofloxacin. Antimicrob Agents Chemother 1993; 37: 1259-63.
38. Cynamon MH, Sklaney M. Gatifloxacin and ethionamide as the foundation for therapy of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2442-4.
39. Ruiz-Serrano MJ, Alcala L, Martinez L, Diaz M, Marin M, Gonzalez-Abad MJ, et al. In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000; 44: 2567-8.
40. Tomioka H, Sato K, Kajitani H, Akaki T, Shishido S. Comparative antimicrobial activities of the newly synthesized quinolone WQ-3034, levofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex. Antimicrob Agents Chemother 2000; 44: 283-6.
41. Kawakami K, Namba K, Tanaka M, Matsuhashi N, Sato K, Takemura M. Antimycobacterial activities of novel levofloxacin analogues. Antimicrob Agents Chemother 2000; 44: 2126-9.
42. Valera L, Gradelski E, Huczko E, Washo T, Yigit H, Fung-Tomc J. In vitro activity of a novel des-fluoro(6) quinolone, garenoxacin (BMS- 284756), against rapidly growing mycobacteria and Nocardia isolates. J Antimicrob Chemother 2002; 50: 140-2.
43. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, et al. In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother 1999; 43: 1077-84.
44. CDC: Core curriculum on tuberculosis: what the clinician should know, Fourth ed. Atlanta, GA: US Department of Health & Human Services, Centers for Disease Control, 2000.
45. Valerio G, Bracciale P, Legari G, Bellanova S. Preliminary results of long term tolerance and effectiveness of moxifloxacin (MXFC) therapy in tuberculosis (TBC). In: American Thoracic Society 99th International Conference. Seattle, WA, 2003.
46. Keiser P, Nassar N, Skiest D, Rademacher S, Smith JW. A retrospective study of the addition of ciprofloxacin to clarithromycin and ethambutol in the treatment of disseminated Mycobacterium avium complex infection. Int J STD AIDS 1999; 10: 791-4.
47. Narita M, Alonso P, Lauzardo M, Hollender ES, Pitchenik AE, Ashkin D. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994-1997. Chest 2001; 120: 343-8.
48. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993; 328: 527-32.
49. Ghebremichael S, Svenson SB, Kallenius G, Hoffner SE. Antimycobacterial synergism of clarithromycin and rifabutin. Scand J Infect Dis 1996; 28: 387-90.
50. Apseloff G, Foulds G, LaBoy-Goral L, Willavize S, Vincent J. Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers. J Clin Pharmacol 1998; 38: 830-5.
51. Mor N, Vanderkolk J, Mezo N, Heifets L. Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium. Antimicrob Agents Chemother 1994; 38: 2738-42.
52. Wallace RJ Jr, Brown BA, Griffith DE, Girard W, Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis 1995; 171: 747-50.
53. Hafner R, Bethel J, Power M, Landry B, Banach M, Mole L, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother 1998; 42: 631-9.
54. Griffith DE. Risk-benefit assessment of therapies for Mycobacterium avium complex infections. Drug Saf 1999; 21: 137-52.
55. Kuper JI, D'Aprile M. Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet 2000; 39: 203-14.
56. Kemper CA, Meng TC, Nussbaum, J, Chiu J, Feigal DF, Bartok AE, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med 1992; 116: 466-72.
57. Watt B. In vitro sensitivities and treatment of less common mycobacteria. J Antimicrob Chemother 1997; 39: 567-74.
58. Tomioka H, Sano C, Sato K, Shimizu T. Antimicrobial activities of clarithromycin, gatifloxacin and sitafloxacin, in combination with various antimycobacterial drugs against extracellular and intramacrophage Mycobacterium avium complex. Int J Antimicrob Agents 2002; 19: 139-45.
59. Shih PH, Bonk S, Rom WN, Harkin TJ. Incidence of quinolone resistance in multi drug-resistant tuberculosis. In: American Thoracic Society 99th International Conference. Seattle, WA, 2003.
60. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, et al. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis. Clin Infect Dis 2003; 37: 1448-52.
61. Ginsburg AS, Hooper N, Parrish NM, Dooley KE, Dorman SE, Booth J, et al. Fluoroquinolone resistance in newly-diagnosed tuberculosis. American Thoracic Society 99th International Conference. Seattle, WA, 2003.
62. Leysen DC, Haemers A, Pattyn SR. Mycobacteria and the new quinolones. Antimicrob Agents Chemother 1989; 33: 1-5.
63. Venkataprasad N, Jacobs MR, Johnson JL, Klopman G, Ellner JJ. Activity of new quinolones against intracellular Mycobacterium avium in human monocytes. J Antimicrob Chemother 1997; 40: 841-5.
64. Yew WW, Piddock LJ, Li MS, Lyon D, Chan CY, Cheng AF. In-vitro activity of quinolones and macrolides against mycobacteria. J Antimicrob Chemother 1994; 34: 343-51.
65. Royo P, Martin-Casabona N, Martinez E, Andonegui M. In vitro susceptibility of Mycobacterium kansasii to the difluorinated quinolone sparfloxacin using a broth microdilution and macrodilution MIC system. Int J Tuberc Lung Dis 1999; 3: 349-53.
66. Brown-Elliott BA, Wallace RJ Jr, Crist CJ, Mann L, Wilson RW. Comparison of in vitro activities of gatifloxacin and ciprofloxacin against four taxa of rapidly growing mycobacteria. Antimicrob Agents Chemother 2002; 46: 3283-5.
67. Dancey JE. Agents targeting ras signaling pathway. Curr Pharm Design 2002; 8(25): 2259-67.
68. Danelishvilli L, Bermudez LE. Role of type I cytokines in host defense against Mycobacterjum avium infection. Curr Pharm Design 2003; 9(1): 61-5.
69. Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, et al. Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons. Curr Pharm Design 2002; 8(22): 1945-58.